The price of Takeda Pharmaceutical Company Limited (NYSE:TAK) shares last traded on Wall Street rose 0.32% to $15.85.
Based on available information, 14 analysts follow Takeda Pharmaceutical Company Limited (NYSE:TAK). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $26.53 and a low of $13.56, we find $16.64. Given the previous closing price of $15.80, this indicates a potential upside of 5.32 percent. TAK stock price is now 3.63% away from the 50-day moving average and 11.63% away from the 200-day moving average. The market capitalization of the company currently stands at $50.42B.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Among analysts, 7 rate the stock a hold while 5 rate it a buy. Brokers who have rated the stock have averaged $17.35 as their price target over the next twelve months.
With the price target enhanced from $21 to $24, Cowen Upgraded its rating from Market Perform to Outperform for Takeda Pharmaceutical Company Limited (NYSE: TAK)., while ‘JP Morgan’ rates the stock as ‘Neutral’.
There have been several recent changes in the stakes of large investors in TAK stock. A new stake in Takeda Pharmaceutical Company Limited shares was purchased by ENDURANT CAPITAL MANAGEMENT LP during the first quarter worth $17,471,000. LMR PARTNERS LLP invested $9,330,000 in shares of TAK during the first quarter. In the first quarter, LEGACY WEALTH ASSET MANAGEMENT, LLC acquired a new stake in Takeda Pharmaceutical Company Limited valued at approximately $2,167,000. NOMURA HOLDINGS INC acquired a new stake in TAK for approximately $2,038,000. SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC purchased a new stake in TAK valued at around $873,000 in the second quarter. In total, there are 329 active investors with 2.10% ownership of the company’s stock.
A candlestick chart of Takeda Pharmaceutical Company Limited (NYSE: TAK) showed a price of $15.70 on Wednesday morning. During the past 12 months, Takeda Pharmaceutical Company Limited has had a low of $12.28 and a high of $16.30. As of last week, the company has a debt-to-equity ratio of 0.71, a current ratio of 1.10, and a quick ratio of 0.70. The fifty day moving average price for TAK is $15.29 and a two-hundred day moving average price translates $14.20 for the stock.
The latest earnings results from Takeda Pharmaceutical Company Limited (NYSE: TAK) was released for Jun, 2022. The net profit margin was 5.70% and return on equity was 3.50% for TAK. The company reported revenue of $7.22 billion for the quarter, compared to $7.69 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -6.13 percent.
Moreover, the firm recently paid out its quarterly dividend on 07/11/2022. Investors who held shares on 03/31/2022 were paid a $0.330062 dividend. On an annualized basis, this represents a $1.06 dividend and a 6.67% percent yield. There was an ex-dividend date of 03/30/2022 for this dividend.
Takeda Pharmaceutical Company Limited(TAK) Company Profile
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., ZEDIRA GmbH, and Dr. Falk Pharma GmbH, as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Leave a Reply